Literature DB >> 19330591

Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences.

Luigi Mariani1, Rosalba Miceli, Silvia Michilin, Massimo Gion.   

Abstract

We studied the diagnostic accuracy of carcinoembryonic antigen (CEA) and cancer antigen 15.3 (CA 15.3) in detecting breast cancer recurrence. Biomarker follow-up determinations, made over 900 patients, were related to local-regional or distant recurrence using statistical models for longitudinal data. The diagnostic accuracy was quantified in terms of sensitivity, specificity and Youden index. The biomarkers were poorly predictive of local-regional recurrence. As for distant recurrence, the best diagnostic accuracy was obtained considering the two biomarkers jointly and combining two positivity criteria: a value above the normal limit or a difference between two consecutive measurements greater than the critical difference for at least one biomarker. A third criterion, based on within-patient comparison between follow-up determinations and a baseline, failed to improve the above result. CEA and CA 15.3 might play a role in patient monitoring during follow-up for the search of distant recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330591     DOI: 10.1080/13547500902770090

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  13 in total

1.  Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?

Authors:  Joseph A Sparano; N Lynn Henry
Journal:  J Natl Cancer Inst       Date:  2019-04-01       Impact factor: 13.506

2.  Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Joseph Sparano; Anne O'Neill; Katherine Alpaugh; Antonio C Wolff; Donald W Northfelt; Chau T Dang; George W Sledge; Kathy D Miller
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

3.  Exploratory investigation of eight circulating plasma markers in brain tumor patients.

Authors:  Aysegul Ilhan-Mutlu; Ludwig Wagner; Georg Widhalm; Adelheid Wöhrer; Sophie Bartsch; Thomas Czech; Harald Heinzl; Fritz Leutmezer; Daniela Prayer; Christine Marosi; Wolfgang Base; Matthias Preusser
Journal:  Neurosurg Rev       Date:  2012-07-05       Impact factor: 3.042

Review 4.  Promoting quality and evidence-based care in early-stage breast cancer follow-up.

Authors:  N Lynn Henry; Lynn N Henry; Daniel F Hayes; Scott D Ramsey; Gabriel N Hortobagyi; William E Barlow; Julie R Gralow
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

5.  Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.

Authors:  Yue Yang; Huijuan Zhang; Mingyan Zhang; Qingwei Meng; Li Cai; Qingyuan Zhang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

6.  Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: preliminary results in the United States.

Authors:  Peter H Wiernik; Dahlia Elkadi; Alvaro Luongo-Cespedes; Julio Battistoni; Silvina Rossi; Susana Caceres; Raul Platero; Norma Piriz; Alvaro Lamas
Journal:  Med Oncol       Date:  2010-01-27       Impact factor: 3.064

7.  Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.

Authors:  Hong-Tai Chang; Chin Hu; Yu-Li Chiu; Nan-Jing Peng; Ren-Shyan Liu
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

8.  An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer.

Authors:  Andrea Nicolini; Angelo Carpi; Paola Ferrari; Riccardo Morganti; Valentina Mazzotti; Vivian Barak; Michael J Duffy
Journal:  Cancer Manag Res       Date:  2018-12-13       Impact factor: 3.989

9.  CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients.

Authors:  Mariarosaria Incoronato; Peppino Mirabelli; Onofrio Catalano; Marco Aiello; Chiara Parente; Andrea Soricelli; Emanuele Nicolai
Journal:  BMC Cancer       Date:  2014-05-21       Impact factor: 4.430

10.  Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.

Authors:  Ryan J O Dowling; Kevin Kalinsky; Daniel F Hayes; Francois-Clement Bidard; David W Cescon; Sarat Chandarlapaty; Joseph O Deasy; Mitch Dowsett; Robert J Gray; N Lynn Henry; Funda Meric-Bernstam; Jane Perlmutter; George W Sledge; Scott V Bratman; Lisa A Carey; Martin C Chang; Angela DeMichele; Marguerite Ennis; Katarzyna J Jerzak; Larissa A Korde; Ana Elisa Lohmann; Eleftherios P Mamounas; Wendy R Parulekar; Meredith M Regan; Daniel Schramek; Vuk Stambolic; Mangesh A Thorat; Timothy J Whelan; Antonio C Wolff; Jim R Woodgett; Joseph A Sparano; Pamela J Goodwin
Journal:  JNCI Cancer Spectr       Date:  2019-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.